Evaluation of hybridisation on oligonucleotide microarrays for analysis of drug-resistant Mycobacterium tuberculosis  by Gryadunov, D. et al.
ORIGINAL ARTICLE 10.1111/j.1469-0691.2005.01183.x
Evaluation of hybridisation on oligonucleotide microarrays for analysis of
drug-resistant Mycobacterium tuberculosis
D. Gryadunov1, V. Mikhailovich1, S. Lapa1, N. Roudinskii1, M. Donnikov1, S. Pan’kov1, O. Markova1,
A. Kuz’min2, L. Chernousova2, O. Skotnikova3, A. Moroz3, A. Zasedatelev1 and A. Mirzabekov1
1Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, 2Central Tuberculosis
Research Institute, Russian Academy of Medical Sciences and 3Moscow Anti-Tuberculosis Center,
Moscow Government, Moscow, Russia
ABSTRACT
A molecular approach was developed to identify drug-resistant strains of Mycobacterium tuberculosis by
means of biochips with oligonucleotides immobilised in polyacrylamide gel pads. The technique was
based on multiplex PCR, followed by hybridisation on an oligonucleotide microarray, and detected
> 95% of rifampicin-resistant and c. 80% of isoniazid-resistant M. tuberculosis isolates within 12 h. In
total, 220 drug-resistant isolates and 131 clinical samples were tested using biochips. The sensitivity and
specificity of the developed method were comparable with those of standard bacteriological testing of
M. tuberculosis drug resistance.
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INTRODUCTION
Mycobacterium tuberculosis remains one of the
leading causes of human morbidity and mortality
worldwide. Early diagnosis, effective treatment
and successful prevention of transmission are
major strategies in the control of tuberculosis
(TB). Current treatment for TB involves a multi-
drug regimen based on rifampicin and isoniazid,
the drugs most effective against M. tuberculosis
infection. Although use of an appropriate drug
with full patient compliance is highly effective
in curing pulmonary TB, the emergence of
M. tuberculosis strains that are resistant to rif-
ampicin and isoniazid reduces the efficacy of
standard treatment [1].
Resistance to rifampicin is determined in 96%
of cases by polymorphisms in an 81-bp DNA
sequence in the rpoB gene (RRDR) [2,3]. Isoniazid
resistance may be caused by mutations located in
several genes (katG, inhA, ahpC) [2,4,5]. Although
the frequency of different isoniazid resistance
mutations varies between different populations,
mutations affect the katG gene most frequently;
these mutations constitute about 95% of resist-
ance mutations in the Latvian population [6] and
about 86% in the Russian population [7]. Several
molecular assays have been developed to screen
these genes for mutations, including heteroduplex
and mismatch analyses, DNA sequencing, real-
time PCR, molecular beacons, hybridisation on
microarrays, and other assays [8–16]. A commer-
cial test, the Inno-LiPa assay, is available for
detection of the four most common mutations in
clinical isolates [17,18].
The approach described in the present paper
used oligonucleotide microarrays (biochips) to
simultaneously detect DNA of the M. tuberculosis
complex and identify mutations that cause rif-
ampicin and isoniazid resistance inM. tuberculosis
isolates from clinical specimens. Using microar-
rays, the analysis of clinical samples requires
< 12 h. The biochip described in the present work
is an improved and more advanced version of a
biochip for identification of rifampicin-resistant
Corresponding author and reprint requests: D. A. Gryadunov,
Engelhardt Institute of Molecular Biology, Russian Academy
of Sciences, 32 Vavilov St, 119991 Moscow, V-334, Russia
E-mail: grad@redline.ru
 2005 Copyright by the European Society of Clinical Microbiology and Infectious Diseases
M. tuberculosis isolates described previously [19].
The present study investigated the use of this
approach as a tool for large-scale clinical and
epidemiological studies, and assessed the specif-
icity, sensitivity and predictive values.
MATERIALS AND METHODS
Mycobacterium isolates and clinical specimens
In total, 220 isoniazid-resistant clinical isolates of M. tubercu-
losis, as well as 113 acid-fast bacillus (AFB)-positive and 20
AFB-negative sputum samples, were analysed. Controls were
standard strains ofM. tuberculosisH37Rv,Mycobacterium avium,
Mycobacterium intracellulare, Mycobacterium kansasii, Mycobacte-
rium fortuitum, Mycobacterium xenopi, Mycobacterium gordonae,
Mycobacterium chelonae and Mycobacterium scrofulaceum.
The 220 clinical isolates were obtained from chronically
disabled patients infected with TB from Moscow and the
Moscow region (one isolate per patient). All isolates were
grown on Lowenstein–Jensen (LJ) medium and were identified
by biochemical tests [20]. Isoniazid susceptibility tests were
carried out by the proportion method on LJ medium contain-
ing isoniazid 0.2 mg ⁄L [20]. Of the 220 isolates, 168 were also
resistant phenotypically to rifampicin, confirmed by incuba-
tion on LJ medium containing rifampicin 40 mg ⁄L (propor-
tional method) [20]. The isolates were considered resistant if
> 1% of colonies grew on the antibiotic-containing medium
compared with the drug-free medium.
The 113 AFB-positive sputum samples were obtained from
primary patients diagnosed with pulmonary tuberculosis by
radiological and clinical criteria [21]. Among the 20 AFB-
negative sputum samples, six were obtained from chronic TB
patients showing poor treatment compliance, while 14 samples
were from individuals with suspected TB, but with an
unconfirmed diagnosis.
The specimens were decontaminated with an equal volume
of N-acetyl-L-cysteine and NaOH 2% w ⁄v, homogenised by
centrifugal swirling, and then incubated for 15 min [22]. The
reaction was neutralised by adding 0.067 M phosphate-buf-
fered saline (pH 6.8) to a final volume of 50 mL. The
specimens were concentrated by centrifugation at 3000 g for
15 min. The supernatant was discarded, and the sediment was
resuspended in 5 mL of sterile water. Part of the sediment
from each specimen was used to inoculate an LJ slant, and the
remaining portion was stored at ) 20C until used for DNA
extraction. LJ slants were incubated at 37C for 6 weeks and
inspected weekly for growth. When growth was detected, a
smear was prepared to confirm the presence of AFB in suspect
colonies by Ziehl–Neelsen staining. Rifampicin and isoniazid
susceptibility tests were carried out by the proportion method
on LJ medium containing rifampicin 40 mg ⁄L and isoniazid
0.2 mg ⁄L, respectively.
Preparation of DNA samples
Frozen decontaminated samples of sputum, or one or two
colonies of M. tuberculosis (2–3 mm in diameter), were resus-
pended in 0.5 mL of TE buffer (10 mM Tris-HCl, 1 mM EDTA,
pH 8.0) and centrifuged at 12 000 g for 10 min at 4C. The
pellet was resuspended in 30 lL of TE buffer containing Triton
X-100 1% v ⁄v and incubated for 30 min at 95C. The extracts
were cooled on ice and centrifuged at 12 000 g for 10 min,
after which 2-lL aliquots of clear supernatant were used in
PCRs.
Oligonucleotides
Oligonucleotides for immobilisation on a biochip (Table 1)
and primers for amplification (Table 2) were designed and
synthesised as described previously [19]. To immobilise
oligonucleotides in gel pads or to attach the indodicarbocy-
anine dye (Biochip-IMB Ltd, Moscow, Russia), an amino
group was introduced during synthesis using 3¢-Amino-
Modifier C7 CPG 500 or 5¢-Amino-Modifier C6 (Glen
Research, Sterling, VA, USA). The attachment of the fluor-
escent group to the oligonucleotide amino group was carried
out according to the manufacturer’s instructions. Oligonu-
cleotides and primers were purified by reverse phase high-
performance liquid chromatography on C18-Nucleosil
columns (Sigma, St Louis, MO, USA). The molecular mass
of each oligonucleotide was measured with a MALDI-TOF
mass spectrometer (COMPACT MALDI 4; Kratos Analytical,
Chestnut Ridge, NY, USA) using sinapinic acid or 2-amino-
5-nitropyridine as a matrix.
Preparation of target DNA for hybridisation on biochips
Target samples of DNA from M. tuberculosis were prepared by
two-stage multiplex PCR. In the first stage, five genome
segments of M. tuberculosis were amplified simultaneously.
The lengths of the fragments were 300 bp (IS6110 loci), 212 bp
(rpoB), 166 bp (katG), 143 bp (inhA) and 126 bp (ahpC). Primers
used for amplification of these segments are listed in Table 2.
Each reaction mix (25 lL) contained 1.5 mM MgCl2, 10 mM
KCl, 10 mM Tris-HCl, pH 8.3, 0.2 mM each dNTP, 5 U of Taq
DNA polymerase (Sileks, Moscow, Russia), 0.5 U of uracyl-
DNA-glycosylase to prevent contamination (Sileks), 50 nM
primers p105f, p293r, katG_f, katG_r1, IS_f and IS_r1, 100 nM
primers inhA_f, inhA_r1, ahpC_f and ahpC_r1, and 2 lL of
DNA sample (10–100 pg). The reactions were carried out in a
MiniCycler (MJ Research, Waltham, MA, USA), with 5 min at
95C, followed by 36 cycles of 30 s at 95C and 40 s at 72C,
and a final extension at 72C for 5 min. Following amplifica-
tion, 1 lL of the reaction mixture was used as a template for
the second PCR round.
In the second reaction, internal fragments of about 100
bases were amplified for each target. The primers used in the
reaction are listed in Table 2. Each PCR mix (50 lL) contained
the following concentrations of primers: p1272f* ⁄p1398r,
100 nM ⁄ 10 nM; katG_f ⁄ katG_r2*, 5 nM ⁄ 50 nM; inhA_f ⁄
inhA_r2*, 10 nM ⁄ 100 nM; ahpC_f ⁄ ahpC_r2*, 5 nM ⁄ 50 nM;
and IS_f ⁄ IS_r2*, 5 nM ⁄ 50 nM. The difference in the concentra-
tions of forward and reverse primers within each pair meant
that each reaction yielded predominantly single-stranded
fluorescently-labelled product. PCRs comprised 5 min at
95C, followed by 42 cycles of 30 s at 95C, 30 s at 65C and
20 s at 72C, with a final extension at 72C for 5 min.
Sequencing
Fragments of genes that determine resistance were amplified
with the corresponding primers (Table 2) and subjected to
dideoxy-sequencing using one of the terminal primers and a
Big DyeDeoxy Terminator SequencingKit with Taq Polymerase
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substitution Sequence 5¢ ﬁ 3¢
Nucleotide positions
in referred sequence
Sequence of rpoB gene (Genbank Acc. No. L27989) rpoB ⁄Acc. No. L27989
A1 507 WT – GCTGTCTGGTGCCGAAGA 2370–2353
A2 507 DEL GGCACC GGCTCAGCTGGCT– — -GAAGAA 2376–2352
B1, F1 510 Gln (WT) CAG GCTCAGCTGGCTGGTGC 2375–2359
B2, F2 510 Gln > His CAG > CAT TGGCTCAGATGGCTGGTG 2377–2360
E3, F3 511 Leu (WT) CTG AATTGGCTCAGCTGGCTG 2380–2364
E4, F4 511 Leu > Pro CTG > CCG AATTGGCTCGGCTGGCT 2380–2364
E5, F5 511 Leu > Arg CTG > CGG AATTGGCTCCGCTGGCT 2380–2364
E8 512 Ser (WT) AGC ATGAATTGGCTCAGCTGGC 2383–2365
E7 512 Ser > Thr AGC > ACC ATGAATTGGGTCAGCTGGC 2383–2365
E6 512 Ser > Arg AGC > CGC ATGAATTGGCGCAGCTG 2383–2367
A8 513 Gln (WT) CAA TCCATGAATTGGCTCAGCT 2386–2368
B8 513 Gln > Leu CAA > CTA TCCATGAATAGGCTCAGCT 2386–2368
C8 513 Gln > Lys CAA > AAA TCCATGAATTTGCTCAGCT 2386–2368
D8 513 Gln > Pro CAA > CCA TCCATGAATGGGCTCAGCT 2386–2368
C1, F6 515 Met (WT) ATG GTTGTTCTGGTCCATGAATTGC 2396–2374
C2, F7 515 Met > Ile ATG > ATA GTTGTTCTGGTCTATGAATTGGC 2396–2374
A3 516 Asp (WT) GAC TTGTTCTGGTCCATGAAT 2397–2376
A4 516 Asp > Val GAC > GTC TTGTTCTGGACCATGAAT 2397–2376
A5 516 Asp > Tyr GAC > TAC TTGTTCTGGTACATGAAT 2397–2376
A6 516 Asp > Gly GAC > GGC TTGTTCTGGCCCATGAAT 2397–2376
A7 516 Asp > Glu GAC > GAG TTGTTCTGCTCCATGAAT 2397–2376
D1 522 Ser (WT) TCG TCAACCCCGACAGCG 2414–2398
D2 522 Ser > Leu TCG > TTG TCAACCCCAACAGCG 2414–2398
B3, C3 526 His (WT) CAC GGCGCTTGTGGGTCAAC 2424–2408
B4 526 His > Asp CAC > GAC GGCGCTTGTCGGTCAAC 2424–2408
B5 526 His > Leu CAC > CTC GGCGCTTGAGGGTCAAC 2424–2408
B6 526 His > Gln CAC > CAA GGCGCTTTTGGGTCAAC 2424–2408
B7 526 His > Cys CAC > TGC GGCGCTTGCAGGTCAAC 2424–2408
C4 526 His > Tyr CAC > TAC GGCGCTTGTAGGTCAAC 2424–2408
C5 526 His > Asn CAC > AAC GGCGCTTGTTGGTCAAC 2424–2408
C6 526 His > Arg CAC > CGC GGCGCTTGCGGGTCAAC 2424–2408
C7 526 His > Pro CAC > CCC GGCGCTTGGGGGTCAAC 2424–2408
D3 531 Ser (WT) TCG CAGCGCCGACAGTCG 2438–2424
D4 531 Ser > Leu TCG > TTG CCAGCGCCAACAGTCG 2439–2424
D5 531 Ser > Trp TCG > TGG CAGCGCCCACAGTCG 2438–2424
D6 531 Ser > Cys TCG > TGT CAGCGCACACAGTCG 2438–2424
D7 531 Ser > Gln TCG > CAG CAGCGCCTGCAGTCG 2438–2424
E1 533 Leu (WT) CTG TGCCCCAGCGCCGACAG 2443–2427
E2 533 Leu > Pro CTG > CCG TGCCCCGGCGCCGACAG 2443–2427
Sequence of katG gene Genbank Acc. No. U06262) katG ⁄ Acc. No. U06262
G1 315 Ser (WT) AGC CGATCACCAGCGGCAT 1004–1019
G2 315 Ser > Thr1 ACC CGATCACCACCGGCAT 1004–1019
G3 315 Ser > Thr2 ACA CGATCACCACAGGCATC 1004–1020
G4 315 Ser > Asn AAC GATCACCAACGGCATC 1005–1020
G5 315 Ser > Ile ATC GATCACCATCGGCATC 1005–1020
G6 315 Ser > Arg1 CGC GATCACCCGCGGCAT 1005–1020
G7 315 Ser > Arg2 AGA ATCACCAGAGGCATCG 1006–1021
G8 315 Ser > Gly GGC GATCACCGGCGGCAT 1005–1019
H1 328 Trp (WT) TGG CGAAATGGGACAACA 1046–1060
H2 328 Trp > Gly GGG CGAAAGGGGACAACA 1046–1060
H3 328 Trp > Leu TTG CGAAATTGGACAACAG 1046–1060
H4 328 Trp > Cys TGC CGAAATGCGACAACA 1046–1060
H5 335 Ile (WT) ATC TCCTCGAGATCCTGTACG 1064–1081
H6 335 Ile > Val GTC TCCTCGAGGTCCTGTACG 1064–1081
Sequence of inhA gene (Genbank Acc. No. AY192027) inhA ⁄Acc. No. AY192027
H8 24 – G (WT) CCGGCCGCGGCG 164–175
H7 24 – G > T CCGGCCTCGGCG 164–175
I8 8 – T (WT) GATAGGTTGTCGGGG 180–194
I7 8 – T > A GATAGGATGTCGGGG 180–194
I6 8 – T > G GATAGGGTGTCGGGG 180–194
I5 15 – C (WT) CGGCGAGACGATAGG 171–185
I4 15 – C > T CGGCGAGATGATAGG 171–181
I3 16 – C > G GGCGAGGCGATAGG 172–185
Sequence of ahpC gene (Genbank Acc. No. U16243 ahpC ⁄ Acc. No. U16243
I1 6 – G (WT) GCACGATGGAATGTCGC 680–696
I2 6 – G >A GCACGATAGAATGTCGCA 679–696
J1 10 – C (WT) TCACGGCACGATGGAA 686–701
J2 10 – C > T TCACGGCATGATGGAA 686–701
J3 10 – C > A TCACGGCAAGATGGAA 686–701
J4 9 – G (WT) CACGGCACGATGGAAT 685–700
J5 9 – G >A CACGGCACAATGGAAT 685–700
J6 12 – C (WT) CTTCACGGCACGATGG 688–703
J7 12 – C > T ACTTCACGGTACGATGGA 687–704
Sequence of IS6110 element (Genbank Acc. No. AF189827) IS6110 ⁄ Acc. No. AF189827
F8, J8 – – WT CCGGAGCTGCGTGAGCG 1359–1375
aThe designations of oligonucleotides correspond to their location in Fig. 1A.
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FS (Applied Biosystems, Foster City, CA, USA). The reaction
products were analysed on an ABI 373A automated sequencer
(Applied Biosystems).
Biochip structure and manufacturing
As described previously [19], gel elements with immobilised
oligonucleotides corresponding to specific potentially mutated
positions were located in groups, in which one element
corresponded to the wild-type sequence, while other ele-
ment(s) carried oligonucleotides complementary to known
mutations. Perfect or imperfect hybridisation duplexes were
formed, depending on the nature of the tested DNA, and the
conditions were selected to maximise the differences in
hybridisation efficiency between perfect and imperfect
duplexes, and therefore between the fluorescence intensity of
positive and negative signals.
The biochip for identification of rifampicin-resistant and
isoniazid-resistant strains of M. tuberculosis contained a set of
71 oligonucleotides (Table 1) in 80 gel pads (nine oligonucle-
otides were duplicated), three marker cells for automatic
processing of fluorescence images, and seven negative control
elements. This biochip detected the 28 most common muta-
tions in the rpoB gene responsible for rifampicin resistance, 11
mutations in the katG gene, five mutations in the promoter
region of the inhA gene, and five mutations in the intergenic
regulatory region of the ahpC–oxyR genes, which cause
resistance to isoniazid. Gel pads with immobilised oligonucle-
otides were clustered in 23 groups (Fig. 1a). Following hybrid-
isation, the fluorescence signals were analysed within each
group separately to determine whether mutation(s) were
present in the amino-acid position concerned.
Gel pads F8 and J8 in Fig. 1a contained oligonucleotides
complementary to the IS6110 sequence, which is present in
most mycobacteria belonging to the M. tuberculosis complex.
Elements K1–K7 contained no oligonucleotides and served as
negative controls. Following hybridisation, the average fluor-
escence intensity in gel pads F8 and J8 was compared with
the average fluorescence of K1–K7. If the ratio exceeded the
prescribed threshold value (derived from statistical data), the
DNA being tested was considered to originate from a strain
belonging to the M. tuberculosis complex.
Biochips for hybridisation were manufactured as described
previously [23] and were supplied with hybridisation cham-
bers (Biochip-IMB, Moscow, Russia). The biochip contained
semi-spherical gel pads, 100 lm in diameter, spaced at 300 lm.
The uniformity of the gel pad printing was determined with
TestChip software (Biochip-IMB). Quality control of large-
scale microchip production was performed by measuring the
quantity of immobilised oligonucleotides in each gel pad.
The biochip was stained with the fluorescent dye ImD-310, and
the concentration of oligonucleotides was determined as
described previously [24].
Hybridisation on biochips and fluorescence measurements
Hybridisation mixtures were prepared by adding 12 lL of the
second-stage PCR mixtures to 24 lL of 1.5 M guanidine
thiocyanate, 0.075 M HEPES, pH 7.5, and 7.5 mM EDTA. The
biochip hybridisation chamber was filled with the mixture and
incubated for 6 h at 37C. Following hybridisation, the cham-
ber was removed and the microarray was washed three times
(about 30 s each) at 37C with 6.5 · SSPE buffer (1 · SSPE
buffer comprises 150 mM NaCl, 100 mM NaH2PO4.H2O,
1 mM EDTA), pH 7.4, containing Tween-20 10% v ⁄v, and
air-dried. The capture of hybridisation fluorescence images,
measurement of signal intensity and normalisation were
performed with a portable fluorescence analyser equipped
with Imageware software (Biochip-IMB).
RESULTS
Molecular identification of mutations resulting in
drug resistance in M. tuberculosis was performed
successfully by hybridisation on the biochip. The
procedure consisted of three successive steps: (1)
multiplex PCR amplification of five DNA frag-
ments; (2) asymmetric semi-nested multiplex PCR
to yield five fluorescently-labelled predominantly
single-stranded DNA fragments; and (3) hybrid-
isation of the labelled fragments on the biochip
with gel pads carrying immobilised oligonucleo-
tides.
Fig. 1b illustrates the hybridisation of a wild-
type target DNA sample with the microarray. The
maximum fluorescence intensity within each
group is seen in gel pads containing oligonucle-
otides corresponding to the wild-type sequence.
Table 2. Primers used in two-stage
PCR for the TB hybridisation tech-
nique





p105f CGTGGAGGCGATCACACCGCAGACGTTG 2288–2315 rpoB ⁄L27989
p293r AGTGAGACGGGTGCACGTCGCGGACCT 2476–2503 rpoB ⁄L27989
P1272f* CGCCGCGATCAAGGAGTTCT 2336–2355 rpoB ⁄L27989
p1398r TCACGTGACAGACCGCCGGG 2442–2461 rpoB ⁄L27989
KatG_f TGGAAGAGCTCGTATGGCACCGGAACC 967–993 katG ⁄U06262
KatG_r1 CGGTGTATTGCCAAGCGCCAGCAG 1109–1132 katG ⁄U06262
katG_r2* GCTCTCCGTCAGCTCCCACTCGTAGCC 2990–3016 katG ⁄U06262
InhA_f CCGGAAATCGCAGCCACGTTACGC 118–141 inhA ⁄AY192027
InhA_r1 GGTAACCAGGACTGAACGGGATACGAA 230–256 inhA ⁄AY192027
inhA_r2* GGCCCCTTCAGTGGCTGTGGCAG 198–220 inhA ⁄AY192027
AhpC_f ATGGTGTGATATATCACCTTTGCCTGACAGC 706–736 ahpC ⁄U16243
AhpC_r1 GGAATTGATCGCCAATGGTTAGCAGTGG 611–638 ahpC ⁄U16243
ahpC_r2* TGACTCTCCTCATCATCAAAGCGGACA 641–667 ahpC ⁄U16243
IS_f AGGATGGGGTCATGTCAGGTGGTTCATCGA 1318–1347 IS6110 ⁄AF189827
IS_r1 GCGAAGAAAGCCGACGCGGTCTTTAAAATC 1598–1627 IS6110 ⁄AF189827
IS_r2* CGCTGCCCACTCCGAATCGTGC 1409–1430 IS6110 ⁄AF189827
f, forward primer; f*, fluorescent-labelled forward primer; r, reverse primer; r*, reverse fluorescent-labelled primer.
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The identification of the tested isolate as a
member of the M. tuberculosis complex is con-
firmed by positive signals in gel pads F8 and J8.
Fig. 1c shows an example of the hybridisation
pattern of a mutant target DNA from a drug-
resistant isolate of M. tuberculosis. A mutation in
the rpoB gene (Ser531 > Leu; TCG > TTG) results
in the formation of a perfect duplex and therefore
a strong fluorescence signal in gel pad D4. The
fluorescence intensity is much higher than in gel
pad D3, where the wild-type probe is immobi-
lised. The isolate shown in Fig. 1c was also
resistant to isoniazid, and the corresponding
mutation was detected similarly. Gel pad G2 has
the strongest fluorescence signal within the group
G1–G8, corresponding to amino-acid position
315 of the katG gene. The intensity of fluores-
cence in G2 is higher than in G1, containing
wild-type oligonucleotide. The detected mutation
(Ser315 > Thr; AGC > ACC) is known to result in
isoniazid resistance [2,4,25].
Analytical sensitivity and specificity
The sensitivity of the microarray was determined
by assaying PCR products generated from
ten-fold serial dilutions of DNA isolated from
the rifampicin-susceptible M. tuberculosis strain
H37Rv. The hybridisation results could be inter-
preted unambiguously with as little as 1 pg of
genomic DNA (corresponding to 200 mycobacte-
rial genomes).
The specificity of the microarray was tested
using DNA from 20 strains of atypical mycobac-
Fig. 1. Analysis of Mycobacterium tuberculosis drug suscep-
tibility by hybridisation on a biochip. (a) The scheme of the
biochip for hybridisation. Gel pads are clustered in 23
groups. The groups are depicted as boxes. Each group
corresponds to a single variable amino-acid position or
variable nucleotide in the promoter regions of the inhA and
ahpC genes. One gel pad within each group contained an
oligonucleotide matching the wild-type sequence (grey
circles). Other gel pads of the group contained immobi-
lised oligonucleotides forming perfect duplexes with dif-
ferent mutant variants of the same codon (white circles).
Thus, only one oligonucleotide in each group could form a
perfect duplex with the target DNA. (b) Hybridisation of a
wild-type DNA sample on the biochip. (c) Hybridisation of
a DNA sample containing the following mutations indica-
ted by arrows: Ser531 > Leu, TCG > TTG in the rpoB gene
(1); Ser315 > Thr, AGC > ACC in the katG gene (2).
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teria: M. avium (five isolates); M. intracellulare
(five); M. kansasii (three); M. fortuitum (three); and
one isolate each of M. xenopi, M. gordonae,
M. chelonae and M. scrofulaceum. The ratio of
fluorescence signals in F8 and J8 to control
elements K1–K7 was ten or higher for M. tuber-
culosis DNA samples. When DNA from non-TB
mycobacteria was tested, the fluorescence signals
in F8 and J8 were close to the signals in control
pads K1–K7 (i.e., a ratio close to 1.00), and the
signals from other gel pads were not analysed. No
false-positive results were observed in the gel
pads corresponding to IS6110.
Analysis of a series of mycobacterial DNA
samples by hybridisation on oligonucleotide
microarrays
Fig. 2 summarises the results obtained following
hybridisation of DNA from 220 isoniazid-resistant
M. tuberculosis isolates on the biochips. In total,
91% of isolates had mutations in the katG gene.
Substitutions in codon 315 were found in 88% of
isolates (Ser > Thr, AGC > ACC; or Ser > Asn,
AGC > AAC). Mutations in the inhA and ahpC
genes were identified in 60% and 7% of isolates,
respectively. Mutations in two genes (katG and
inhA) were found simultaneously in 118 (54%)
DNA samples, while four isolates had mutations
in both katG and ahpC.
Among the 220 isoniazid-resistant isolates, 168
were also resistant phenotypically to rifampicin.
Mutations in the rpoB gene were found by
hybridisation with 164 (75%) samples. The
Ser531 and His526 amino-acid substitutions were
found most frequently (Fig. 2). Four rifampicin-
resistant isolates showed the wild-type hybridi-
sation pattern, and sequencing of the rpoB gene
fragments confirmed the absence of mutations
inside the 81-bp hypervariable rpoB region for
these isolates. In this context, it is accepted
generally that about 5% of rpoB mutations con-
ferring rifampicin resistance occur outside the
RRDR [26].
Comparison of identification results obtained by
the hybridisation technique and conventional
drug susceptibility testing for sputum
specimens
In total, 113 samples of AFB-positive and 20
samples of AFB-negative sputum were tested.
Each specimen was examined by hybridisation
and by conventional bacteriological methods,
with determination of rifampicin and isoniazid
resistance by the proportional method (see Mate-
rials and Methods). Comparison of the data
obtained (Table 3) revealed five false-negative
samples, in that one rifampicin-resistant and
four isoniazid-resistant isolates appeared to be
Table 3. Comparison of rifampicin and isoniazid susceptibilities of Mycobacterium tuberculosis in acid-fast bacillus-positive
sputum specimens, as assessed by hybridisation and conventional drug susceptibility testing
Conventional testing by









Detected as RIF-resistant Detected as RIF-susceptible
Detected as RIF-resistant 18 17 1 100 94.0 100 99
Detected as RIF-susceptible 95 0 95
Total 113 17 96
Detected as INH-resistant Detected as INH-susceptible
Detected as INH-resistant 24 21 4 100 84.0 100 96
Detected as INH-susceptible 89 0 88
Total 113 21 92
INH, izoniazid; RIF, rifampicin.
Fig. 2. Distribution of mutations as revealed by hybridi-
sation analysis of 220 DNA samples from izoniazid-
resistant Mycobacterium tuberculosis isolates. The genes
and amino-acid ⁄nucleotide substitutions are represented
below each bar, and the corresponding numbers of isolates
are indicated on the vertical axis.
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susceptible by the biochip method. The absence of
mutations in the corresponding gene fragments
was confirmed by sequencing. As described
above, 5% of rpoB mutations conferring rifampi-
cin resistance occur outside the RRDR; similarly,
5–15% of isoniazid-resistant isolates may have
mutations in other segments of the katG, ahpC and
inhA genes, or in other genes [2,27].
Six AFB-negative sputum samples from chronic
patients yielded the hybridisation pattern shown
in Fig. 1c. The substitutions Ser531 > Leu in the
rpoB gene and Ser315 > Thr in the katG gene were
found in all samples. The presence of drug-
resistant TB was confirmed by growth on medium
containing isoniazid and rifampicin in appropri-
ate concentrations.
Among 14 AFB-negative samples from indi-
viduals with suspected TB, only two yielded
growth on LJ medium, and no growth was
observed on medium containing rifampicin or
isoniazid. Corresponding results were obtained
with the biochips, with analysis of DNA from the
two positive samples yielding hybridisation pat-
terns associated with wild-type M. tuberculosis.
No fluorescence signals were observed on the
biochips with the other samples in this set.
DISCUSSION
This study describes the further development of
the hybridisation-based approach for the detection
of drug resistance in M. tuberculosis, both in
cultures and in clinical samples, using the plat-
form of gel-based oligonucleotide microarrays.
The previous generation of biochips, MAGIChips
[19], were of inconsistent quality, yielding insuf-
ficient reproducibility and uneven distribution of
immobilised oligonucleotides within individual
gel elements. In addition, the technology required
for their manufacture was rather complex, slow
and inefficient for large-scale production. To
overcome the shortcomings of MAGIChips, which
consisted of rectangular gel elements formed in a
special mould, a new co-polymerisation proce-
dure was developed [23] for the production of
microchips consisting of drop semi-spherical
elements. This technology simplified the fabrica-
tion of biochips and increased their quality signi-
ficantly. For large-scale production, all
oligonucleotides and primers are analysed by
high-performance liquid chromatography and
MALDI-TOF mass spectrometry, while other
quality controls include determining the uniform-
ity of the gel pads and quantifying the concentra-
tion of immobilised oligonucleotide in each gel
pad using fluorescence dye [24].
These new biochips offer several advantages
for drug resistance testing in clinical laboratory
diagnostics. The most important improvement in
the new generation of biochips is that better
discrimination between the perfect and mis-
matched duplexes leads to accurate and reliable
identification [23]. This enables the analysis of
specific sequences using a minimal set of oligo-
nucleotides that is necessary and sufficient for
identification of known mutations. The latter
consideration decreases the cost of chip manufac-
ture dramatically, simplifies the read-out of the
results, and eliminates the need for cumbersome
mathematical processing. The ability to discrim-
inate between perfect and imperfect duplexes for
each pair of oligonucleotides immobilised on the
biochip was assessed by the ratio r = Ip ⁄ Im, where
Ip is the normalised fluorescence of the gel pad
corresponding to a perfect duplex, and Im is the
normalised fluorescence of the gel pad corres-
ponding to an imperfect duplex. The calculated
ratio was within the range 2.0–20 for all positions,
which is sufficient for unambiguous interpret-
ation of the hybridisation pattern.
In the experiments with isoniazid-resistant iso-
lates, 215 of 220 isolates carried mutations, as
determined by hybridisation with the biochip, and
would be classified correctly as isoniazid-resistant
in the clinical situation. Hence, the accuracy of the
hybridisation procedure was c. 98%. The frequent
occurrence of rpoB mutations in isoniazid-resist-
ant isolates (c. 75% of isolates) confirms the
suggestion that rifampicin resistance is a strong
surrogate marker of multidrug-resistant TB
strains [5]. Twelve isoniazid-resistant isolates
were observed to have mutations in the regulatory
region of the ahpC gene, with wild-type katG and
inhA gene loci. It is now considered that mutations
in the promoter region of ahpC compensate for low
or reduced katG expression in isoniazid-resistant
isolates, but are not involved directly in isoniazid
resistance [28,29]. A possible explanation of the
results in the present study is that only part of the
katG gene (116 bp) is amplified and analysed with
the biochip. Additional studies may be required to
determine the necessity for biochip expansion to
detect less frequent isoniazid resistance mutations
in different geographical areas. Nevertheless, the
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biochip is able to identify unambiguously muta-
tions at codon 315 of the katG gene that have been
associated with a high level of isoniazid resistance
[30], as well as mutations in the inhA gene, and
thus the positive results obtained by this assay are
clinically very useful. The results confirmed that
the biochips used in the present study are specific
for the M. tuberculosis complex, thereby distin-
guishing the causative agent of TB from non-
tuberculous mycobacteria.
The detection of rifampicin and isoniazid sus-
ceptibility in AFB-positive sputum specimens
obtained from primary patients with TB correla-
ted well with bacteriological testing (Table 3). The
frequency of multidrug-resistant TB strains in
primary patients in the Moscow region is about
15%. The specificity of the procedure (i.e., the
ability to detect true susceptibility) was 100% for
both drugs, while the sensitivity of the procedure
(i.e., the ability to detect true resistance) was 94%
for rifampicin and 84% for isoniazid. The results
obtained with smear-negative sputa showed that
the biochip technique could be applied for
analysis of samples from chronically disabled
patients. In addition, a good correlation with the
conventional standard technique was obtained
when testing individuals with suspected TB who
had AFB-negative sputum.
Combined, these data indicate that hybridisa-
tion with the biochip is a reliable approach for
the detection of drug-resistant causative agents of
TB. Although reuse of biochips is not recom-
mended, this technique allows up to 100 sam-
ples ⁄day to be analysed. The analysis requires
< 12 h, is much faster than the most advanced
methods based on bacteriological cultivation [31],
and performs at least as well as another special-
ised microarray for rifampicin susceptibility test-
ing [14] or the INNO-LiPA Rif.TB kit [17,18].
Furthermore, the new biochip-based approach
allows simultaneous analysis of different
segments of the mycobacterial genome, is inex-
pensive (c. 11 euro ⁄ sample), and can be imple-
mented in clinical laboratories with very basic
equipment when compared to the requirements
of high-density DNA probe arrays [15,16]. In
contrast to real-time PCR [12], the method iden-
tifies the exact nucleotide substitution involved
as opposed to the simple presence of mutations.
The application of the biochip method in clinical
practice will lead to the treatment of TB with
timely medication correction, and will help to
prevent the spread of multidrug-resistant
M. tuberculosis strains.
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